Bestatin as adjuvant treatment in operated stage I and stage II non-small cell lung cancer. European Lung Cancer Study Group.
The aim of this study is to evaluate the possible effect of bestatin with respect to disease-free survival and overall survival. The study was designed as a randomized, two-armed study with surgery + bestatin in one arm, versus surgery alone in the other arm. All patients randomized are followed for 5 years or until death. By January 1st 1988, 1,030 patients had been randomized, but less than 50% were eligible after pathological staging. The data seem to show a trend in favour of bestatin in terms of disease-free survival, but the trend is far from being significant. No serious side-effects have been reported. No final conclusions can be drawn at present by April 1st 1988, but follow-up will continue and a new analysis made by April 1st 1989.
Mouritzen
C
C
Department of Thoracic and Cardiovascular Surgery, Skejby Sygehus, Arhus, Denmark.
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008198:Lymph Nodes / Q000473:pathology; D009367:Neoplasm Staging; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D007930:Leucine; C012211:ubenimex